At Roche Pharmaceuticals, we focus on finding new medicines that help patients live longer, better lives and evolve the practice of medicine.
Below is a list of Roche medicines that are available in New Zealand. Use the search function to search by active ingredient, brand name or disease area, to find the Data Sheet and Consumer Medicine Information (CMI) for each product.
If you have a question about a Roche medicine, please Contact Us.
- Actemra® (tocilizumab) Infusion T
-
Actemra® (tocilizumab) Supply Shortage
Roche is currently experiencing shortages of multiple presentations of Actemra® (tocilizumab) in New Zealand. This is due to a global demand for Actemra that has increased significantly in response to the COVID-19 pandemic. A patient level stockout for Actemra concentrate for solution for intravenous infusion is expected from October 2021.
Roche is working closely with Medsafe and Pharmac to minimise the impact on patients in New Zealand and preserve stock for critical patients.
Supply constraints will be in effect to mitigate against stockpiling and to support availability of product. For some patients there may be a period of time when Actemra IV is unavailable until early 2022.
During the pandemic the demand for Actemra has been increasing at a global level. Roche has been working urgently to increase manufacturing capacity and supply. We have been maximising our own production network, as well as actively working with external manufacturers on transferring our technologies to further increase global supply.
The global supply situation for Actemra is evolving as the pandemic continues to impact patients around the world. We will provide further information as the situation evolves.
Further information can be found on the Medsafe (www.medsafe.govt.nz/safety/DHCPLetters.asp) and PHARMAC (www.pharmac.govt.nz/medicine-funding-and-supply/medicine-notices/tocilizumab/?mType=2&updatedWithin=7days) websites.
This material contains off-label information on Actemra that has not been registered by Medsafe. Actemra is not licensed for the treatment of COVID-19. No recommendations regarding safety and efficacy can be made for such unapproved uses. Any treatment decisions based on the information provided are the full responsibility of the prescribing physician. Before prescribing, please review the Actemra Data Sheet at www.medsafe.govt.nz.
M-NZ-00000431/SEPT 2021
Actemra® (tocilizumab)
Uses of Actemra® (tocilizumab) Infusion:
- Treatment of moderate to severe rheumatoid arthritis in adults, as well as certain types of systemic juvenile idiopathic arthritis and polyarticular juvenile idiopathic arthritis
More Information
- Actemra® (tocilizumab) SC (subcutaneous injection)
-
Actemra® (tocilizumab) SC (subcutaneous injection)
Uses of Actemra® (tocilizumab) SC (subcutaneous injection):
- Treatment of moderate to severe rheumatoid arthritis and giant cell arteritis in adults
More Information
- Alecensa® (alectinib hydrochloride)
-
Alecensa® (alectinib hydrochloride)
Uses of Alecensa® ((alectinib hydrochloride):
- Treatment of advanced (metastatic) ALK-positive non-small cell lung cancer
More Information
- Avastin® (bevacizumab)
-
Avastin® (bevacizumab)
Uses of Avastin® (bevacizumab):
- Treatment of advanced (metastatic) bowel, kidney, breast, brain, lung, ovarian and cervical cancers
More Information
- CellCept® (mycophenolate mofetil)
-
CellCept® (mycophenolate mofetil)
Uses of CellCept® (mycophenolate mofetil):
- Treatment to prevent rejection of transplanted organs
More Information
- Cotellic® (cobimetinib)
-
Cotellic® (cobimetinib)
Uses of Cotellic® ® (cobimetinib):
- Treatment of advanced (metastatic) melanoma
More Information
- Erivedge® (vismodegib)
-
Erivedge® (vismodegib)
Uses of Erivedge ® (vismodegib):
- Treatment of advanced (metastatic) basal cell carcinoma
More Information
- Esbriet® (pirfenidone)
-
Esbriet® (pirfenidone)
Uses of Esbriet ® (pirfenidone):
- Treatment of Idiopathic Pulmonary Fibrosis (IPF)
More Information
- Gazyva® (obinutuzumab)
-
Gazyva® (obinutuzumab)
Uses of Gazyva ® (obinutuzumab):
- Treatment of previously untreated chronic lymphocytic leukaemia (CLL) and indolent non hodgkin lymphoma (iNHL)
More Information
- Hemlibra® (emicizumab)
-
Hemlibra® (emicizumab)
Uses of Hemlibra ® (emicizumab):
- Treatment of congenital haemophilia A with or without factor VIII inhibitors
More Information
- Herceptin® (trastuzumab) SC (subcutaneous injection)
-
Herceptin® (trastuzumab)SC (subcutaneous injection)
Uses of Herceptin ® (trastuzumab)SC (subcutaneous injection):
- Treatment of early and advanced (metastatic) HER2-positive breast cancer
More Information
- Herceptin® (trastuzumab) IV
-
Herceptin® (trastuzumab) IV
Uses of Herceptin ® (trastuzumab) IV:
- Treatment of HER2-positive early and metastatic breast cancer and for HER2-ve advanced gastric cancer.
More Information
- Kadcyla® (trastuzumab emtansine)
-
Kadcyla® (trastuzumab emtansine)
Uses of Kadcyla ® (trastuzumab emtansine):
- Kadcyla is indicated for the second-line treatment of HER2-positive metastatic breast cancer and adjuvant treatment in early HER2-positive breast cancer.
More Information
- MabThera® (rituximab)
-
MabThera® (rituximab)
Uses of MabThera ® (rituximab):
- Treatment of non-Hodgkin’s lymphoma (NHL) and chronic lymphocytic leukaemia (CLL)
More Information
- Mabthera RA® (rituximab)
-
Mabthera RA® (rituximab)
Uses of Mabthera RA ® (rituximab):
- Treatment of rheumatoid arthritis, granulomatosis with polyangiitis and microscopic polyangiitis
More Information
- Madopar® (levodopa and benserazide)
-
Madopar (levodopa and benserazide)
Uses of Madopar ® (levodopa and benserazide):
- Treatment of Parkinson’s disease
More Information
- NeoRecormon® (epoetin beta)
-
NeoRecormon (epoetin beta)
Uses of NeoRecormon ® (epoetin beta):
- Treatment of Anaemia
More Information
- Ocrevus® (ocrelizumab)
-
Ocrevus (ocrelizumab)
Uses of Ocrevus ® (ocrelizumab):
- Treatment of relapsing forms of multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS)
More Information
- Pegasys® (peginterferon alfa-2a)
-
Pegasys (peginterferon alfa-2a)
Uses of Pegasys ® (peginterferon alfa-2a):
- Treatment of hepatitis B and C
More Information
- Perjeta® (pertuzumab)
-
Perjeta® (pertuzumab)
Uses of Perjeta ® (pertuzumab):
- Treatment of HER2-positive early breast cancer either before or after surgery (neoadjuvant or adjuvant) and advanced (metastatic) breast cancer
More Information
- Pulmozyme® (dornase alfa)
-
Pulmozyme® (dornase alfa)
Uses of Pulmozyme ® (dornase alfa):
- Treatment of cystic fibrosis
More Information
- Rivotril® (clonazepam) injection and oral solution
-
Rivotril® (clonazepam) injection and oral solution
Uses of Rivotril ® ( clonazepam) injection and oral solution:
- Treatment of epilepsy
More Information
- ROZLYTREK® (entrectinib)
-
ROZLYTREK® (entrectinib)
Uses of ROZLYTREK ® (entrectinib):
- Treatment of ROS1+ non-small cell lung cancer
- Treatment of NTRK+ solid tumours
More Information
- Tamiflu® (oseltamivir)
-
Tamiflu® (oseltamivir)
Uses of Tamiflu ® (oseltamivir):
- Treatment of influenza
More Information
- Tarceva® (erlotinib)
-
Tarceva® (erlotinib)
Uses of Tarceva ® (erlotinib):
- Treatment of non-small cell lung cancer
More Information
- Tecentriq® (atezolizumab)
-
Tecentriq® (atezolizumab)
Uses of Tecentriq ® (atezolizumab):
- Treatment of metastatic non-small cell lung cancer, extensive-stage small cell lung cancer, metastatic urothelial carcinoma and metastatic triple-negative breast cancer.
More Information
- Valcyte® (valganciclovir)
-
Valcyte® (valganciclovir)
Uses of Valcyte ® (valganciclovir):
- Treatment and prevention of cytomegalovirus (CMV)
More Information
- Zelboraf® (vemurafenib)
-
Zelboraf® (vemurafenib)
Uses of Zelboraf ® (vemurafenib):
- Treatment of advanced (metastatic) melanoma
More Information
Responsible Marketing
The promotion and sale of pharmaceutical and diagnostics products is highly regulated. Roche has a strong commitment to comply with all applicable laws, regulations and industry codes.
In New Zealand our marketing practices are regulated and guided by the following Acts and Codes.
- The Medicines Act 1981 and Medicines Regulations 1984
- Advertising Standards Authority Therapeutic and Health Advertising Code
- Medicines New Zealand (MNZ) Code of Practice.
- The Medical Technology Association of New Zealand Code (MTANZ) Code of Practice.
- Therapeutic Advertising Pre-vetting System (TAPS)